[HTML][HTML] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy
G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - Respiratory …, 2015 - Springer
Background Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled
corticosteroid (ICS)/long-acting beta 2 agonist (LABA) treatment approved in the United …
corticosteroid (ICS)/long-acting beta 2 agonist (LABA) treatment approved in the United …
Bronchodilator reversibility in COPD
NA Hanania, BR Celli, JF Donohue, UJ Martin - Chest, 2011 - Elsevier
COPD is a preventable and treatable disease characterized by airflow limitation that is not
fully reversible. The diagnosis of COPD is based on spirometric evidence of airways …
fully reversible. The diagnosis of COPD is based on spirometric evidence of airways …
Salmeterol & Fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already …
RW Dal Negro, C Pomari, S Tognella… - Pulmonary pharmacology …, 2003 - Elsevier
Bronchodilator agents are central to the symptomatic management of Chronic Obstructive
Pulmonary Disease (COPD), and long-acting inhaled bronchodilators are regarded as more …
Pulmonary Disease (COPD), and long-acting inhaled bronchodilators are regarded as more …
Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD
MR Partridge, W Schuermann… - Therapeutic …, 2009 - journals.sagepub.com
Background: Patients with chronic obstructive pulmonary disease (COPD) often experience
symptoms and problems with activities early in the morning. This is the first study to compare …
symptoms and problems with activities early in the morning. This is the first study to compare …
[HTML][HTML] A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford, S Rennard… - Respiratory …, 2013 - Elsevier
BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD
L Sichletidis, J Kottakis, S Marcou… - … journal of clinical …, 1999 - Wiley Online Library
We studied 27 patients with stable chronic obstuctive pulmonary disease (COPD) in a
randomised, single‐blind, within‐patient, placebo‐controlled clinical study. Each patient was …
randomised, single‐blind, within‐patient, placebo‐controlled clinical study. Each patient was …
Withdrawal from treatment as an outcome in the ISOLDE study of COPD
PMA Calverley, S Spencer, L Willits, PS Burge… - Chest, 2003 - Elsevier
Objectives To investigate the determinants of patient withdrawal from our study, and the
effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in …
effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in …
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study
BR Celli, NE Thomas, JA Anderson… - American journal of …, 2008 - atsjournals.org
Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by an
accelerated decline in lung function. No drug has been shown conclusively to reduce this …
accelerated decline in lung function. No drug has been shown conclusively to reduce this …
The severity of airways obstruction as a determinant of treatment response in COPD
PMA Calverley, RA Pauwels, PW Jones… - … Journal of Chronic …, 2006 - Taylor & Francis
Guidelines recommend that patients with COPD are stratified arbitrarily by baseline severity
(FEV1) to decide when to initiate combination treatment with a long-acting β2-agonist and …
(FEV1) to decide when to initiate combination treatment with a long-acting β2-agonist and …
Long-Acting Inhaled β2-Agonists for Stable COPD
JA Dougherty, BL Didur… - Annals of …, 2003 - journals.sagepub.com
OBJECTIVE: To describe the pathogenesis of chronic obstructive pulmonary disease
(COPD) and mechanisms of benefit, formulations available, drug costs, pharmacokinetic …
(COPD) and mechanisms of benefit, formulations available, drug costs, pharmacokinetic …